Editorial:

GENETIC VARIANTS CONFER SUSCEPTIBILITY TO URINARY BLADDER CANCER: AN UPDATED LIST OF CONFIRMED POLYMORPHISMS

Silvia Selinski

Leibniz Institut für Arbeitsforschung an der TU Dortmund, Leibniz Research Centre for Working Environment and Human Factors (IfADo), Ardeystrasse 67, 44139 Dortmund, Germany

selinski@ifado.de

Urinary bladder cancer is the 7th most common cancer in Western Europe (Ferlay et al., 2012). The most relevant risk factors are occupational exposure to aromatic amines and polycyclic aromatic hydrocarbons as well as cigarette smoking (Golka et al., 2012, 2009, 2004; Schwender et al., 2012). Moreover, polymorphisms of phase II metabolizing enzymes are well-known since decades to increase bladder cancer risk, in particular, the deletion variant of the phase II metabolizing enzyme glutathione-S-transferase M1 (GSTM1) (Ovsiannikov et al., 2012; Golka et al., 2009, 1997; Arand et al., 1996) and polymorphisms in the N-acetyltransferase 2 (NAT2) gene leading to a reduced acetylation capacity (Selinski et al., 2011; Moore et al., 2011; Golka et al., 2002, 1996), and currently their influence on prognosis is investigated (Roth et al., 2012; Nørskov et al., 2011). Recently, genome-wide association studies (GWAS) have identified several novel nucleotide polymorphisms (SNPs) as associated with urinary bladder cancer (UBC) risk and most of them could be confirmed in independent follow-up case-control series (review: Golka et al., 2011; Table 1). So far SNPs at ten chromosomal locations, besides GSTM1, have been identified. The functions of the closest genes are related to maintenance of DNA integrity, apoptosis and cell cycle control as well as detoxification of carcinogens. Considering the large size of the case-control series with more than 4,500 cases and 45,000 controls (Rafnar et al., 2011; Kiemeney et al., 2010; Rothman et al., 2010), the high density of polymorphisms on SNP chips as well as the accuracy of SNP imputation algorithms it may be regarded as likely that the most influential SNPs have now been discovered. However, one open question remains: to date it is completely unknown, if the novel SNPs interact. If so, will they result in less than additive, additive or even over additive risks? How high is the population attributable risk of the combined influence of all polymorphisms? And how important is the combined genetic risk compared to the risk attributable to cigarette smoking and occupational exposure to bladder carcinogens? Considering the recent progress in genome-wide association studies it can be expected that answers to these questions will soon be available.

First analyses beyond the standard single SNP analyses in case-control designs yield promising results (Binder et al., 2012; Menashe et al., 2012; Schwender et al., 2012).
Table 1: Currently confirmed genetic variants that are associated with bladder cancer risk. Polymorphisms and related genes are printed bold, risk alleles are given in brackets.

| Key message                                                                                                                                                                                                 | Reference                                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| Rs9642880[T] near proto-oncogene MYC (v-myc myelocytomatosis viral oncogene homolog (avian) was associated with UBC in a GWAS (OR=1.22). The effect of rs9642880[T] was less pronounced in cases with suspected exposure to bladder carcinogens (OR=1.04 and 1.11 exposed study groups; OR=1.36 non-exposed) for which GSTM1 null is the more important genetic risk factor (OR=2.43 and 1.38 exposed; OR=1.22 non-exposed). | Kiemene et al., 2008; Golka et al., 2009 |
| Rs710521[A] near the TP63 (tumor protein 63) gene, that encodes for a member of the p53 family of transcription factors, was associated with UBC in a GWAS (OR=1.19). The effect of rs710521[A] on UBC risk (OR=1.16) did not depend on exposure to bladder carcinogens via tobacco smoke or occupation. | Kiemene et al., 2008; Lehmann et al., 2010 |
| Rs401681[C] in an intron of CLPTM1L (cisplatin resistance related protein CRR9p) and the nearby synonymous rs2736098[A] in the 2nd exon of TERT (telomerase reverse transcription) were both associated with UBC in a GWAS (OR=1.12; OR=1.16). The CLPTM1L gene associated with cisplatin-induced apoptosis and the nearby TERT that is involved in telomere maintenance and thus in aging are located at a potential cancer susceptibility locus at 5p15.33. | Rafnar et al., 2009 |
| Rs2294008[T] alters the start codon of PSCA (prostate stem cell antigen) leading to a reduced promoter activity in vitro and was associated with UBC in a GWAS (OR=1.15). PSCA is over-expressed in prostate and bladder tumors. | Wu et al., 2009 |
| Rs2978974[A] in an alternative untranslated 1st exon of PSCA was associated with UBC in a fine-mapping study (OR=1.11) and interacted with rs2294008 10 kb upstream rs2978974. | Fu et al., 2012 |
| Rs798766[T] in an intron of TACC3 (transforming, acidic coiled-coil containing protein 3), 70 kb of FGFR3 (fibroblast growth factor receptor 3) was associated with UBC in a GWAS (OR=1.24). | Kiemene et al., 2010 |
| Rs11892031[C] in an intronic region in the UGT1A (UDP glucuronosyltransferase 1 family, polypeptide A complex locus) cluster was associated with UBC in a GWAS (OR=0.84) showing a protective effect of the minor allele [C]. UGT1A proteins are involved in the metabolisms of bladder carcinogens via glucuronidation. | Rothman et al., 2010 |
| Rs11892031[C] showed a more pronounced protective effect in persons with occupational exposure to polycyclic aromatic hydrocarbons and aromatic amines (OR=0.68 exposed; OR=0.83 all combined). | Selinski et al., 2012 |
| Rs17863783[T] a synonymous rare (2 %) SNP in a UGT1A6 exon was shown to increase UGT1A6.1 mRNA expression in vitro and was associated with UBC in a fine-mapping study (OR=0.55). Rs17863783 explained most of the effect of rs11892031. | Tang et al., 2012 |
| Rs1495741[A] a tagSNP for NAT2 (N-acetyltransferase 2) activity, 14 kb 3’ of NAT2, was associated with UBC in a GWAS (OR[A/A]=1.15). Polymorphisms of NAT2 lead to a reduced acetylation of drugs and xenobiotics (“slow” and “rapid” acetylators) and are a well-known risk factor for UBC. The A/A genotype tags the slow phenotype. Increased risks were observed in current smokers (OR=1.25). | Rothman et al., 2010 |
| NAT2 tagSNP rs1495741[A/A] showed an excellent specificity (0.94) regarding the phenotype but was outperformed by the common NAT2 genotype (1.00) and a 2-SNP genotype (1.00) based on the known NAT2 SNPs in Caucasians. | Selinski et al., 2011 |
Table 1 (cont.): Currently confirmed genetic variants that are associated with bladder cancer risk. Polymorphisms and related genes are printed bold, risk alleles are given in brackets.

| Key message | Reference |
|-------------|-----------|
| Rs8102137[C] near CCNE1 (cyclin E1) involved in the cell cycle G1/S phase transition was associated with UBC in a GWAS (OR=1.13). CCNE1 over-expression seems to be associated with tumorigenesis and UBC prognosis. | Rothman et al., 2010 |
| Rs1014971[T] 25 kb from CBX6 (chromobox homolog 6) and 64 kb from APOBEC3A (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A) was associated with UBC in a GWAS (OR=1.14). | Rothman et al., 2010 |
| The well-known increased UBC risk of GSTM1 null genotypes was confirmed in a GWAS (OR=1.47). | Rothman et al., 2010 |
| Rs1058396[G] in SLC14A1 (solute carrier family 14 (urea transporter), member 1 (Kidd blood group)) exon 8 leading to an amino acid exchange and rs17674580[T] in an intron of the same gene are associated with UBC in a GWAS (OR=1.14; OR=1.17). SLC14A1 is involved in maintenance of a constant urea concentration gradient in the kidney. Rs1058396 (D280N) determines two alleles of the Kidd blood system. Rs17674580 explained the effect of rs1058396. | Rafnar et al., 2011 |

REFERENCES

Arand M, Mühlbauer R, Hengstler J, Jäger E, Fuchs J, Winkler L et al. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 1996;236:184-6.

Binder H, Müller T, Schwender H, Golka K, Steffens M, Hengstler JG et al. Cluster-localized sparse logistic regression for SNP data. Stat Appl Genet Mol Biol 2012 Aug 14;11(4). pii: /j/sagmb.2012.11.issue-4/1544-6115.1694/1544-6115.1694.xml. http://dx.doi.org/10.1515/1544-6115.1694

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon: International Agency for Research on Cancer, 2010. Available from: http://globocan.iarc.fr, accessed on Nov 09, 2012.

Fu YP, Kohaar I, Rothman N, Earl J, Figueroa JD, Ye Y et al. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proc Natl Acad Sci U S A 2012;109:4974-9.

Golka K, Prior V, Blaszkewicz M, Cascorbi I, Schöps W, Kierfeld G et al. Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand J Work Environ Health 1996;22:332-8.

Golka K, Reckwitz T, Kempkes M, Cascorbi I I, Blaskewicz M, Reich SE et al. N-Acetyltransferase 2 (NAT2) and glutathione S-transferase μ (GSTM1) in bladder-cancer patients in a highly industrialized area. Int J Occup Environ Health 1997;3:105-10.

Golka K, Prior V, Blaszkewicz M, Bolt HM. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol Lett 2002;128:229-41.

Golka K, Wiese A, Assennato G, Bolt HM. Occupational exposure and urological cancer. World J Urol 2004;21:382-91.
Golka K, Hermes M, Selinski S, Blaszkewicz M, Bolt HM, Roth G et al. Susceptibility to urinary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure. Pharmacogenet Genom 2009;19:903-6.

Golka K, Selinski S, Lehmann ML, Blaszkewicz M, Marchan R, Ickstadt K et al. Genetic variants in urinary bladder cancer: collective power of the "wimp SNPs". Arch Toxicol 2011;85:539-54.

Golka K, Kopps S, Prager HM, Mende S v, Thiel R, Jungmann O et al. Bladder cancer in crack testers applying azo dye-based sprays to metal bodies. J Toxicol Environ Health A 2012;75:566-71.

Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, Stacey SN et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 2008;40:1307-12.

Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010;42:415-9.

Lehmann ML, Selinski S, Blaszkewicz M, Orlich M, Ovsianikov D, Moormann O et al. Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk. Arch Toxicol 2010;84:967-78.

Menashe I, Figueroa JD, Garcia-Closas M, Chatterjee N, Malats N, Picornell A et al. Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background. PLoS One 2012;7:e29396.

Moore LE, Baris DR, Figueroa JD, Garcia-Closas M, Karagas MR, Schwenn MR et al. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis 2011;32:182-9.

Nørskov MS, Frikk-Schmidt R, Bojesen SE, Nordestgaard BG, Loft S, Tybjærg-Hansen A. Copy number variation in glutathione-S-transferase T1 and M1 predicts incidence and 5-year survival from prostate and bladder cancer, and incidence of corpus uteri cancer in the general population. Pharmacogenomics J 2011;11:292-9.

Ovsianikov D, Selinski S, Lehmann ML, Blaszkewicz M, Moormann O, Haenel MW et al. Polymorphic enzymes, urinary bladder cancer risk, and structural change in the local industry. J Toxicol Environ Health A 2012;75:557-65.

Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009;41:221-7.

Rafnar T, Vermeulen SH, Sulem P, Thorleifsson G, Aben KK, Witjes JA et al. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet 2011;20:4268-81.

Roth E, Selinski S, Schikowsky C, Seidel T, Volkert F, Blaszkewicz M et al. Bladder cancer survival in a former industrial area in Saxony-Anhalt, Germany. J Toxicol Environ Health A 2012;75:1216-25.

Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010;42:978-84.
Schwender HR, Selinski S, Blaszkewicz M, Marchan R, Ickstadt K, Golka K et al. Distinct SNP combinations confer susceptibility to urinary bladder cancer in smokers and non-smokers. Plos One 2012; accepted.

Selinski S, Blaszkewicz M, Lehmann ML, Ovsiannikov D, Moormann O, Guballa C et al. Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet Genomics 2011;21:673-8.

Selinski S, Lehmann ML, Blaszkewicz M, Ovsiannikov D, Moormann O, Guballa C et al. Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk. Arch Toxicol 2012;86:1369-78.

Tang W, Fu YP, Figueroa JD, Malats N, Garcia-Closas M, Chatterjee N et al. Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. Hum Mol Genet 2012;21:1918-30.

Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 2009;41:991-5. Erratum in Nat Genet 2009;41:1156.